GlassScriptPhysician profile
Michael M Dehning
NPI 1063473056
$5,090.30
in general payments reported to CMS, 2019-2025
34 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $691 · 2021: $643 · 2022: $1,636 · 2023: $310 · 2024: $398 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $564.72 | 2019-2025 | |
| Amgen INC. | $548.06 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $425.69 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $350.78 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $305.25 | 2021-2025 | Camzyos |
| Esperion Therapeutics, INC. | $304.14 | 2020-2022 | |
| Pfizer INC. | $249.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.19 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.32 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $168.22 | 2020-2025 | |
| Medicure Pharma INC. | $158.82 | 2020 | |
| Sanofi-Aventis U.S. LLC | $152.86 | 2019-2021 | |
| Heartflow, INC. | $148.75 | 2025 | |
| Boston Scientific Corporation | $146.00 | 2024 | Watchman Flx |
| Abbott Laboratories | $139.31 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $129.00 | 2025 | Sotalol Hydrochloride |
| Alnylam Pharmaceuticals INC. | $123.16 | 2022 | |
| Scpharmaceuticals INC. | $121.43 | 2024 | |
| Bridgebio Pharma, INC. | $107.61 | 2025 | Attruby |
| Amarin Pharma, INC. | $87.85 | 2020-2021 | |
| Philips North America LLC | $66.84 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $63.74 | 2021-2022 | |
| Gilead Sciences, INC. | $44.58 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $33.63 | 2024 | |
| Cardiva Medical, INC. | $30.82 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Actelion Pharmaceuticals US, INC. | $30.12 | 2021-2022 | |
| Octapharma USA, INC. | $26.03 | 2025 | Fibryga |
| Regeneron Healthcare Solutions, INC. | $22.63 | 2025 | Evkeeza |
| Medtronic Vascular, INC. | $21.66 | 2019 | |
| Averitas Pharma INC. | $20.55 | 2023 | Qutenza |
| Zimmer Biomet Holdings, INC. | $19.58 | 2020 | |
| Grifols USA, LLC | $17.32 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $17.13 | 2024 | Arcalyst |
| Pharmacosmos Therapeutics INC. | $15.24 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dehning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.